Not mentioned much on the call was newly approved cancer drug ERIVEDGE which is licensed from Curis $CRIS - but sales since launch in late January were reported as being $5.5m for the quarter, meaning that royalties to Curis are miniscule at this point (most estimates I have seen indicate mid single digit royalties).
Access the entire transcript at Morningstar.
Check out all the companies I cover, with my new real-time valuation updates on the Stocks page.